Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biosciences Raises $109M in Latest Financing Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences today said that it has raised $109 million in a Series F round of financing.

The firm did not disclose the investors in the round, other than Gen-Probe, which recently made a $50 million investment in PacBio. As a result of the investment, Gen-Probe now holds an approximately 7 percent stake in PacBio.

Gen-Probe and PacBio also are exploring co-development of new integrated diagnostic systems based on PacBio's Single Molecule Real Time platform and Gen-Probe's diagnostics expertise.

"These funds will be used to support our operations as we begin ramping production capabilities for the commercial launch of our PacBio RS system," Hugh Martin, Chairman and CEO of Menlo Park, Calif.-based Pacific Biosciences, said in a statement.

The firm's RS system is based on its Single Molecule Real Time technology and is scheduled for commercial launch for research applications later this year.

PacBio said that it has raised around $370 million since its inception.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.